Third Rock raises $516m for early-stage venture deals
This article was originally published in Scrip
Executive Summary
Third Rock Ventures has raised $516 million for its third life science venture capital fund with a primary focus on therapeutics startups, bringing the Boston-based firm's total capital raised since 2007 to $1.3 billion - all to finance early-stage companies.
You may also be interested in...
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.